QuantaMatrix Past Earnings Performance
Past criteria checks 0/6
QuantaMatrix has been growing earnings at an average annual rate of 14.6%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 63.6% per year.
Key information
14.6%
Earnings growth rate
42.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 63.6% |
| Return on equity | -160.4% |
| Net Margin | -497.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How QuantaMatrix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,605 | -17,943 | 13,527 | 5,200 |
| 31 Mar 24 | 3,483 | -20,221 | 14,376 | 5,361 |
| 31 Dec 23 | 3,118 | -21,556 | 15,550 | 5,778 |
| 30 Sep 23 | 1,606 | -20,469 | 13,875 | 6,067 |
| 30 Jun 23 | 1,460 | -19,688 | 13,318 | 5,806 |
| 31 Mar 23 | 1,333 | -19,537 | 13,431 | 5,608 |
| 31 Dec 22 | 1,286 | -19,237 | 12,837 | 5,492 |
| 30 Sep 22 | 1,098 | -20,083 | 13,464 | 5,308 |
| 30 Jun 22 | 901 | -19,672 | 13,033 | 5,144 |
| 31 Mar 22 | 789 | -19,057 | 12,267 | 5,077 |
| 31 Dec 21 | 550 | -18,116 | 11,406 | 5,122 |
| 30 Sep 21 | 673 | -16,594 | 10,788 | 4,572 |
| 30 Jun 21 | 665 | -15,963 | 10,043 | 4,556 |
| 31 Mar 21 | 1,736 | -15,073 | 9,183 | 4,717 |
| 31 Dec 20 | 1,689 | -14,659 | 8,567 | 4,776 |
| 30 Sep 20 | 1,885 | -15,569 | 8,841 | 5,488 |
| 30 Jun 20 | 1,834 | -17,023 | 8,738 | 5,736 |
| 31 Mar 20 | 709 | -40,791 | 8,467 | 5,638 |
| 31 Dec 19 | 811 | -63,811 | 8,123 | 5,202 |
| 31 Dec 18 | 85 | -16,009 | 6,111 | 4,050 |
| 31 Dec 17 | 47 | -12,423 | 4,247 | 3,459 |
Quality Earnings: A317690 is currently unprofitable.
Growing Profit Margin: A317690 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A317690 is unprofitable, but has reduced losses over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare A317690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A317690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A317690 has a negative Return on Equity (-160.36%), as it is currently unprofitable.